Hypogonadism* (män) Erytrocytos Kardiovaskulär risk
|
|
- Valerie Casey
- 5 years ago
- Views:
Transcription
1 Hypogonadism* (män) Erytrocytos Kardiovaskulär risk *Lågt Testosteron och symtom Stefan Arver ANOVA, Karolinska Univ Sjukhuset Inst. F Medicin/Huddinge Karolinska Institutet Endokrindagar i Umeå
2 The story about testosterone... for his work on sex hormones. (Brown-Séquard, C. The Lancet 1889; 134 (3438); ) Endokrindagar i Umeå
3 N. Engl. J. Med. 1940; 222: From this report of the practical use of testosterone in clinical medicine it is obvious that the drug is a potent one, particularly in hypogonadism in males. In this condition, its effectiveness as substitution therapy is uniformly accepted. Endokrindagar i Umeå
4 The story about testosterone (Lesser, M. N Engl J Med 1943; 228: ) Endokrindagar i Umeå
5 Testosterone in coronary heart disease Mathur A et al. European Journal of Endocrinology
6 När Testosteron Kommer på agendan undrar man Dina Associationer? Förklaring till att män dör tidigare än kvinnor Ökar risken för hjärtkärlsjukdom Styr mäns aggressivitet och gör män våldsamma Ökar sexdrift och potens Hierarkin på jobbet styrs av testosteron Endokrindagar i Umeå
7 Testosteronanvändning i USA Patterns of testosterone prescription overuse. Jasuja, Guneet; Bhasin, Shalender; Rose, Adam Current Opinion in Endocrinology, Diabetes & Obesity. 24(3): , June DOI: /MED FIGURE 1. Proportion of male Veterans receiving testosterone therapy, FY FY: Fiscal Year Data source: VA Corporate Data Warehouse. Endokrindagar i Umeå Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. Published by Lippincott Williams & Wilkins, Inc. 2
8 Low Testosterone and Increased Mortality (N >500) Studies HR (95% CI) Nature Men, n Follow-Up, y Mortality Shores, ( ) Retrospective All-cause Laughlin, ( ) Prospective CVD Khaw, ( ) Prospective 2314 of 11, All-cause and CVD Haring, ( ) Prospective All-cause 2.56 ( ) CVD Malkin, ( ) Prospective All-cause in men with coronary disease Tivesten, ( ) Prospective All-cause Menke, ( ) Prospective All-cause Vikan, ( ) Prospective All-cause Corona, ( ) Prospective CVD HR=hazard ratio; CI=confidence interval. Lunch Seminarium Endokrin Huddinge
9 Epidemiologi och observation Progression of mean IMT of common carotid artery after 4 years correlates with serum total and free testosterone Muller M et al Circulation 2004;109:2074 Mulller M et al. Circulation 2004; 109:
10 JAMA Aug 11;314(6): doi: /jama Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. Basaria S et al Intervention Endokrindagar i Umeå
11 High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men The MrOS (Osteoporotic Fractures in Men) Study in Sweden Claes Ohlsson, MD, PHD,* Elizabeth Barrett-Connor, MD, Shalender Bhasin, MD, PHD, Eric Orwoll, MD, PHD, Fernand Labrie, MD, PHD, Magnus K. Karlsson, MD, PHD,# Östen Ljunggren, MD, PHD,** Liesbeth Vandenput, PHARMD, PHD,* Dan Mellström, MD, PHD,* Åsa Tivesten, MD, PHD Conclusion: High serum testosterone predicted a reduced 5-year risk of CV events in elderly men. (J Am Coll Cardiol 2011; 58: ) 2011 by the American College of Cardiology Foundation Testosterone Therapy Pros and Cons ESSM 2014
12 Vigen R et al. J Am Med Assoc 310(17): (2013) Endokrindagar i Umeå
13 Proportion of All Events According to Kaplan-Meier Estimation with Treatment as Time-Varying Covariate (Stabilized Inverse Probability of Treatment Weighting*) 30 no TRT TRT at 1 year at 2 years at 3 years *age, race, comorbidities: (prior MI, congestive heart failure, diabetes, renal failure, depression, posttraumatic stress disorder, hyperlipidemia, peripheral vascular disease, chronic pulmonary disease, chronic obstructive pulmonary disease, obstructive sleep apnea, hypertension, cerebrovascular disease, overweight, dialysis, ever smoker, alcohol, anemia, blood loss anemia, coagulation disorder, complicated diabetes, uncomplicated diabetes, drug abuse, fluid electrolyte disorder, human immunodeficiency syndrome or AIDS, hypothyroidism, liver disease, lymphoma, metastatic cancer, neurological disorder, paralysis, peptic ulcer disease, psychoses, pulmonary circulatory disorder, renal failure, rheumatoid arthritis, nonmetastatic tumor, and weight loss), and procedures (prior revascularization, prior catheterization, prior percutaneous coronary intervention [PCI], prior coronary artery bypass graft surgery, cardiac transplant, prior stress test, prior cardiac blood pool imaging, cardiac magnetic resonance imaging, cardiac computed tomography [CT], CT coronary angiography, prior myocardial perfusion imaging,,prior transthoracic echocardiogram, and prior transesophageal echocardiogram Endokrindagar i Umeå Data from: Vigen R et al. J Am Med Assoc 310(17): (2013)
14 Proportion of All Events (Composite of All-cause Mortality, Myocardial Infarction and Stroke) in Hypogonadal Patients (%) with or without Testosterone Replacement Therapy (TRT) no TRT TRT 25 21, , Death Myocardial infarction Stroke 0 all events Data from: Vigen R et al. J Am Med Assoc 310(17): (2013) Endokrindagar i Umeå
15 Vascular survival Testosterone, coronary artery disease and prognosis 930 men with coronary heart disease followed for 7 years Bio T >2.6 nmol/l Bio T <2.6 nmol/l Low testosterone levels are common in men with coronary artery disease and low bioavailable but not total testosterone related to impaired vascular survival (Malkin 5 februari et al Heart 2010; 96: ) 15 Days
16 Cumulative survival Cumulative survival Testosterone treatment in T2DM Cohort study (n=581) of men with T2DM followed for 6 years Low TT treated TT 300 ng/dl TT>300 ng/dl Low TT untreated Normal TT p=0.009 HR=2.0 ( ) p=0.004 HR=2.3 ( ) Months of survival Months of survival Low total testosterone (TT) associated with worse prognosis in men with T2DM. Long-term testosterone treatment assessed retrospectively was associated with improved survival in men with low testosterone. 5 februari (Muraleedharan et al. European Journal of Endocrinology 2013: )
17 Odds Ratio for Major Adverse Cardiovascular Events (MACE) in Subjects Treated with Testosterone or Placebo MACE: cardiovascular death, non-fatal myocardial infarction, stroke, acute coronary syndromes, and/or heart failure Odds ratio for MACE TRT Placebo Source MH - OR LL UL p #Events # Patients #Events # Patients Copenhagen SG, 1986 (31) 1,97 0,08 48,82 0,68 Hall et al., 1996 (34) 0,32 0,01 8,23 0,49 Sih et al., 1997 (36) 0,88 0,05 15,33 0,93 Snyder et al., 1999 (40) 2,04 0,18 23,17 0,57 English et al., 2000 (42) 3,12 0,12 80,39 0,49 Seidman et al., 2001 (47) 0,41 0,02 10,83 0,59 Steidle et al., 2003 (52) 2,83 0,11 70,27 0,53 Armory et al., 2004 (54) 3,13 0,12 80,68 0,49 Kenn et al., 2004 (56) 0,23 0,01 7,05 0,40 Svartberg et al., 2004 (60) 0,29 0,01 7,74 0,46 Brockenbrough et al., 2006 (63) 3,75 0,36 39,59 0,27 Malkin et al., 2006 (69) 2,17 0,19 25,01 0,53 Nair et al., 2006 (72) 5,70 0,26 123,78 0,27 Svartberg et al., 2008 (81) 3,16 0,12 82,64 0,49 Chapman et al., 2009 (84) 1,00 0,05 20,83 1,00 Legros et al., 2009 (85) 1,01 0,04 25,01 1,00 Aversa et al., 2010 (89) 0,08 0,00 2,07 0,13 Aversa et al., 2010 (90) 0,07 0,00 1,97 0,12 Basaria et al., 2010 (11) 13,39 0,74 240,78 0,08 Kalinchenko et al., 2010 (92) 0,21 0,01 5,15 0,34 Srinivas- Shankar et al., 2010 (93) 1,01 0,14 7,31 0,99 Ho et al., 2011 (95) 1,00 0,06 16,37 1,00 Jones et al., 2011 (96) 0,51 0,05 5,75 0,59 Kaufman et al (97) 0,87 0,04 18,48 0,93 Behre et al (99) 2,95 0,12 72,91 0,51 Hildreth et al (100) 0,15 0,02 1,53 0,11 Overall 1,01 0,57 1,77 0,96 LL: Lower limit; MH-OR: Mantel-Haenszel odds ratio; UL: Upper limit Placebo Corona G et al. Expert Opin Drug Saf, published online August 19, 2014 TS Endokrindagar i Umeå
18 Lunch Seminarium Endokrin Huddinge
19 There have been no RCTs that were large enough or long enough to determine the effects of T-replacement therapy on major adverse cardiovascular events (MACE). Additionally, there is no conclusive evidence that T supplementation is associated with increased cardiovascular risk in hypogonadal men. Endocrine Soc Guidlines 2018 Endokrindagar i Umeå
20 1. EMA Press Release Accessed [March 2018] at: errals_document/testosterone_31/recommendation_provided_ by_pharmacovigilance_risk_assessment Committee/WC pdf; 2. FDA Drug Safety EMA and FDA recommendations for CV disease risk EMA recommendations Inconsistent evidence for increased risk of CV disease following TRT 1 FDA recommendations TRT labels must specify possible increased risk of stroke and heart attack associated with TRT 2 CV, cardiovascular; EMA, European Medicines Agency; FDA, Food and Drug Administration; TRT, testosterone replacement therapy
21 Testosterone treatment in the cardiovascular system Exercise-induced ischemia: Time to 1 mm ST depression Myocardial perfusion: Perfusion of coronary territories with no stenosis QT interval: QT-interval Changes in CV surrogate measures with testosterone treatment Hemodynamics: Cardiac output Coronary artery blood flow: Blood flow and artery diameter Myocardial protection: Decreased reperfusion injury (Jones et al. Asian J Andrology (2018) 20, ; Endokrindagar Kloner et al. J i Am Umeå Coll 2019 Cardiol 2016;67:545 57) 21
22 Total testosterone (ng/dl) Study I: Dynamics of testosterone 123 male patients with AMI and 124 matched healthy controls Testosterone levels in patients after AMI compared to controls at baseline p< p=0.05 p< Day 1 Discharge 3 months 12 months Controls Time point Anne Wang 5 februari
23 Endokrindagar i Umeå
24 Endokrindagar i Umeå
25 Endokrindagar i Umeå
26 Endokrindagar i Umeå
27 Endokrindagar i Umeå
28 Hematocrit Testosterone Estradiol
29 Effekt av androgen receptor polymorfism på erytropoes respons av T-behandling From: Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long- Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men J Clin Endocrinol Metab. 2007;92(10): doi: /jc
30 Endokrindagar i Umeå
31 Endokrindagar i Umeå
32 Endokrindagar i Umeå
33 Endokrindagar i Umeå
34 Bachman et al J Gerontology A Biol Sci Med 2014 (6): Endokrindagar i Umeå
35 Clinicians should evaluate men who develop erythrocytosis during T-replacement therapy and withhold T therapy until hematocrit has returned to the normal range and then resume T therapy at a lower dose. Using therapeutic phlebotomy to lower hematocrit is also effective in managing T treatment induced erythrocytosis Endocrine Soc Guidlines 2018 Endokrindagar i Umeå
Take-Home Messages: Androgens
Take-Home Messages: Androgens Anthony J. Bella MD, FRCSC Greta and John Hansen Chair in Men s Health Research Division of Urology, Department of Surgery University of Ottawa SUMMARY SLAMS Symposium Clinical
More informationDisclosures. Faculty 3/5/18. Testosterone, the FDA and CVD Risk Controversies. Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI
Testosterone, the FDA and CVD Risk Controversies Faculty Matt Rosenberg, MD Director of Mid-Michigan Health Centers Jackson, MI 2 Disclosures Matt Rosenberg, MD serves on the advisory board for Bayer,
More informationDisclosures. Advisory Boards 6/10/2014
Massachusetts Medical Society 12 th annual Men s Health Symposium 11 June 2014 Testosterone and Cardiovascular Disease Where Does The Real Answer Lie? Andre Guay MD, FACP, FACE, IF (Ret) Director, Center
More informationTestosterone Therapy in Men An update
Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None
More informationProf Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA
Prof Dato Dr TAN Hui Meng University of Malaya, Kuala Lumpur University of Pennsylvania, USA Prevailing context Increase number of men who are potential candidates for Testosterone Replacement Therapy
More informationErectile Dysfunction, Cardiovascular Risk and
Erectile Dysfunction, Cardiovascular Risk and Testosterone National Lipid Association (NLA) 2016 Fall Clinical Update August 26-28, 2016 Amelia Island, Fl Robert A. Kloner MD, PhD Director of the Cardiovascular
More informationTable S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
More informationIL RUOLO DEL DEFICIT DI TESTOSTERONE NELLA SINDROME METABOLICA E NELLA INSUFFICIENZA RENALE NEL MASCHIO ADULTO. VA Giagulli
IL RUOLO DEL DEFICIT DI TESTOSTERONE NELLA SINDROME METABOLICA E NELLA INSUFFICIENZA RENALE NEL MASCHIO ADULTO VA Giagulli UOS di Endocrinologia e Malattie Metaboliche PT di Conversano ASL BA Male hypogonadism
More informationFLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES
http://www.lef.org/ FLAWED TESTOSTERONE ANALYSIS SPURS MISLEADING MEDIA HEADLINES By Blake Gossard, Kira Schmid, ND, Luke Huber, ND, MBA, Steven V. Joyal, MD The precipitous decline of men's testosterone
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationThe reality of LOH-symptoms
The reality of LOH-symptoms PRISM IV Bruges, Belgium September 25-26, 2014 Dr. Herman Leliefeld Androsmannenkliniek The Netherlands The reality of LOH symptoms male external & internal genitalia Testosterone
More informationAssociation of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels
Research Original Investigation Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels Rebecca Vigen, MD, MSCS; Colin I. O Donnell, MS;
More informationUpdate on diagnosis and complications of adult and elderly male hypogonadism
Hypoandrogenism in the elderly: to treat or not to treat? 12 th Italian AME Meeting; 6 th joint Meeting with AAC Bari november 10th Update on diagnosis and complications of adult and elderly male hypogonadism
More informationENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN
ENDOCRINOLOGICAL IMPLICATIONS AND COMPLICATIONS OF TESTOSTERONE REPLACEMENT IN AGEING MEN Frederick C.W. Wu Professor of Medicine and Endocrinology Andrology Research Unit, Centre for Endocrinology and
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationSupplementary Online Content
Supplementary Online Content Dharmarajan K, Wang Y, Lin Z, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. doi:10.1001/jama.2017.8444 etable
More informationAn Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health
An Idea Whose Time Has Come-Male Health Programs: An Opportunity For Clinical Expansion and Better Health KEVIN R. LOUGHLIN MD,MBA Harvard Medical School Boston, MA THE WEAKER SEX-MALES LIFE EXPECTANCY
More informationDisclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None
Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationThe Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease
Journal of the American College of Cardiology Vol. 43, No. 4, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.10.031
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationRecommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men
Recommendations on the diagnosis, treatment and monitoring of Testosterone deficiency (TD) in adult men Bruno Lunenfeld, George Mskhalaya, Svetlana Kalinchenko, Yulia Tishova, Michael Zitzmann, Stefan
More informationNEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS
NEW DEVELOPMENTS: T & CVD FDA & THE T TRIALS 2017 UPDATE FDUS Martin Miner MD Clinical Professor of Family Medicine and Urology Co-Director The Men s Health Center The Miriam Hospital Warren Albert School
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationSupplementary Online Content
Supplementary Online Content Khera R, Dharmarajan K, Wang Y, et al. Association of the hospital readmissions reduction program with mortality during and after hospitalization for acute myocardial infarction,
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationHow to treat: TRT modalities and formulations
How to treat: TRT modalities and formulations Paul PIETTE, PharmD Senior Research Fellow Clinique Antoine Depage - Belgium ppiette@besins-healthcare.com Bruges 2014, May 15 th Testosterone-replacement
More informationEFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE
EFFICACY AND SAFETY OF TESTOSTERONE THERAPY FOR LATE-ONSET HYPOGONADISM: AN UPDATE Matthew Ho, PGY-2 Department of Urologic Sciences University of British Columbia OBJECTIVES 1. Review the characteristics
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationIs it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationPrimary Care Updates ACP conference 2015
Primary Care Updates ACP conference 2015 Richard Rose, MD FACP Assistant Professor University of Utah Department of General Internal Medicine VAMC - Internal Medicine Nothing to disclose Conflicts of interest
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationPoint-Counterpoint: Late Onset Hypogonadism (LOH)
Point-Counterpoint: Late Onset Hypogonadism (LOH) We are Under-diagnosing and Treating Men with LOH LOH is a Non-existent Disease ~ Robert E. Donohue, MD Late Onset Hypogonadism LOH: underdx. & undertx
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationAshwini S Erande MPH, Shaista Malik MD University of California Irvine, Orange, California
The Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction using ARRAYS, PROC FREQ and PROC LOGISTIC ABSTRACT Ashwini S Erande MPH,
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationAppendix Identification of Study Cohorts
Appendix Identification of Study Cohorts Because the models were run with the 2010 SAS Packs from Centers for Medicare and Medicaid Services (CMS)/Yale, the eligibility criteria described in "2010 Measures
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSupplementary Online Content
Supplementary Online Content Basaria S, Harman SM, Travison TG, et al. The effects of testosterone administration for three years on subclinical atherosclerosis progression in older men with low or low
More informationIntensity: 0-10 (10 is the worse pain you have ever experienced in your life that you would want to jump from a building, 0 is no pain)
Patient Questionnaire: Name: Date: Occupation: Date of Birth: Age: Sex: Male Female Referring Physician: Chief Complaint: Describe your Pain: sudden onset gradual constant intermittent worsening improving
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationTestosterone Replacement Therapy and Cardiovascular Risk: A Review
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 December 33(3): 130-142 http://dx.doi.org/10.5534/wjmh.2015.33.3.130 Review Article Testosterone Replacement Therapy and Cardiovascular Risk:
More informationPOOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS
POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS CHARLES A. HERZOG, M.D., JENNIE Z. MA, PH.D., AND ALLAN J. COLLINS, M.D. ABSTRACT Background Cardiovascular
More informationThe presenter does not have any potential conflicts of interest to disclose
Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Outcome Measures (Claims Based)
Last Updated: Version 4.3 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARD FOR HOSPITAL CARE Measure Information Form Collected For: CMS Outcome Measures (Claims Based) Measure Set: CMS Readmission Measures Set
More informationESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH
ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME: INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH AUTHORS: Marta Ponte 1, RICARDO
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationIntraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )
Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland
More informationMetformin. Sulfonylurea. Thiazolidinedione. Insulin
동아의대내분비내과박미경 Metformin Sulfonylurea Thiazolidinedione Insulin 요약 markers of inflammation (hs-crp, TNF-a) markers of impaired endothelial function (VFW, scams, tpa, PAI-1) LDL-C, fasting and postprandial
More informationSupplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.
SUPPLEMENTAL MATERIAL Supplemental Table 1. Standardized Serum Creatinine Measurements Supplemental Table 2. List of ICD 9 and ICD 10 Billing Codes Supplemental Table 3. Sensitivity Analyses with Additional
More informationFY 2011 WISEWOMAN Approved ICD-9 Code List
243 Congenital hypothyroidism 245.0 Thyroiditis; Acute thyroiditis 245.1 Thyroiditis; Subacute thyroiditis 245.2 Thyroiditis; Chronic lymphocytic thyroiditis 245.3 Thyroiditis; Chronic fibrous thyroiditis
More informationHEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM
REVIEW DATE REVIEWER'S ID HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM : DISCHARGE DATE: RECORDS FROM: Hospitalization ER Please check all that may apply: Myocardial Infarction Pages 2, 3,
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationOutline. Classic Androgen deficiency. Cardiovascular Risk and Testosterone Fact vs Fiction. Professor Robert I McLachlan AM, FRACP, PhD
Health Ed Brisbane Saturday 27 th October 2018 Cardiovascular Risk and Testosterone Fact vs Fiction Professor Robert I McLachlan AM, FRACP, PhD Hudson Institute of Medical Research, Monash University Department
More informationThis event does not qualify for continuing medical education (CME), continuing nursing education (CNE), or continuing education (CE) credit
Welcome to this program sponsored by AstraZeneca The educator, who is presenting on behalf of AstraZeneca, is here to provide educational information pertinent to understanding the risk of a recurrent
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationImpaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events
Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More informationARRHYTHMIAS AND DEVICE THERAPY
Topic List A BASICS 1 History of Cardiology 2 Clinical Skills 2.1 History Taking 2.2 Physical Examination 2.3 Electrocardiography 2.99 Clinical Skills - Other B IMAGING 3 Imaging 3.1 Echocardiography 3.2
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationCindy L. Grines MD FACC FSCAI
Cindy L. Grines MD FACC FSCAI Hofstra Northwell School of Medicine Chair, Cardiology Academic Chief of Cardiology, Northwell Health North Shore University Hospital, Manhasset NY Multivessel Disease in
More informationExercise treadmill testing is frequently used in clinical practice to
Preventive Cardiology FEATURE Case Report 55 Commentary 59 Exercise capacity on treadmill predicts future cardiac events Pamela N. Peterson, MD, MSPH 1-3 David J. Magid, MD, MPH 3 P. Michael Ho, MD, PhD
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationQuale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor
Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor Leonardo Bolognese Cardiovascular Department, Arezzo, Italy Platelet Reactivity in Patients with STEMI Undergoing Primary PCI Campo G et
More informationThe Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction
PharmaSUG 2014 - Paper HA06 The Association of Morbid Obesity with Mortality and Coronary Revascularization among Patients with Acute Myocardial Infarction ABSTRACT Ashwini S Erande MPH University Of California
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationSUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index
SUPPLEMENTAL MATERIAL Supplemental Methods Duke CAD Index The Duke CAD index, originally developed by David F. Kong, is an angiographic score that hierarchically assigns prognostic weights (0-100) based
More informationCLINICAL COURSE, MANAGEMENT AND IN-HOSPITAL OUTCOMES
Open Access Research Journal, www.pieb.cz Medical and Health Science Journal, MHSJ ISSN: 1804-1884 (Print) 1805-5014 (Online) Volume 5, 2011, pp. 10-15 CLINICAL COURSE, MANAGEMENT AND IN-HOSPITAL OUTCOMES
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationSupplement Table 1. Definitions for Causes of Death
Supplement Table 1. Definitions for Causes of Death 3. Cause of Death: To record the primary cause of death. Record only one answer. Classify cause of death as one of the following: 3.1 Cardiac: Death
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More information